MONITORING THE TREATMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS WITHIN THE SCOPE OF THE BRAZILIAN UNIFIED HEALTH SYSTEM (SUS)

Abstract

Rheumatoid Arthritis (RA) is a chronic systemic inflammatory disease that can lead to functional limitations, affecting work capacity and quality of life, with significant personal and social impact. In Brazil, the Unified Health System (SUS) provides a wide range of medications for treatment, including biological drugs, some of which are relatively new and represent a high financial burden. However, there are few real-world studies in the country regarding these treatments, which are essential for understanding issues related to adherence, access, benefits, and associated risks. Therefore, the aim of this study was to analyze data from the remote monitoring of RA patients by pharmacists. An observational and prospective study was conducted with RA patients receiving treatment through CEAF (Specialized Component of Pharmaceutical Assistance) during the second half of 2020 and the first half of 2021. Data were collected from the electronic system used and from quarterly telephone consultations. The information was recorded in an electronic tool developed to include data such as: sociodemographic and socioeconomic characteristics, type of healthcare services used, current medications, RA signs and symptoms, and laboratory test results to assess treatment effectiveness and safety. Data were analyzed using Microsoft Excel®. Most participants were female (86.7%, n=263), with a mean age of 59.1 years. At the first consultation, most patients were using synthetic drugs or biologicals combined with synthetics. At the second consultation, the use of biologicals or biologicals combined with synthetics prevailed. Regarding Adverse Drug Reactions (ADRs), 41.4% of users reported no reactions, particularly those using methotrexate. This study analyzed the sociodemographic profile and medication use among RA patients treated at a public pharmaceutical service (CEAF). Thus, the present proposal aims to provide support for improving pharmaceutical care within SUS, identifying gaps in care, and addressing treatment-related needs, thereby contributing to better patient outcomes and quality of life.